Biosynth has opened its Biological Technology site at Lifebay — a technology park in Suzhou, China.
The novel site's bio laboratory, according to the company, will boost its internal project development capacity.
It will also enhance Biosynth's capability to offer material supply services to the domestic life science market.
Biosynth's laboratory will also act as a distribution and handling hub for regional customers.
The official opening ceremony was held on October 29, with local and national dignitaries, as well as pharma customers showing up to mark the occasion.
Representatives of Biosynth's leadership team and its Board Representative, Nico Haller — Director at KKR — were also in attendance.
Philip Noone, Chief Commercial Officer, commented: “Through our new Lifebay facility in Suzhou, Biosynth will serve IVD companies across China directly, with our comprehensive biologics, chemicals, and complex peptides offering. Our new site will allow us for the first time in our history to offer our unique diagnostic solutions for infectious diseases, oncology and autoimmunity targeting emerging pathogens.”
General Manager for China, Alessandra Vismara, added: “This has been a significant project to build and equip this facility. As part of the next phase, we will be commissioning our biosafety level 2 laboratories, which means that we can handle and supply even more biological diagnostic tools. Enzyme development and production for local customers will complete the portfolio of these facilities.”
